Pimavanserin

Pimavanserin sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis and is also being researched for the treatment of Alzheimer’s disease psychosis, schizophrenia, agitation, and major depressive disorder. Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist. Use of pimavanserin is associated with a low rate of serum enzyme elevations during therapy, and it has not been linked to instances of clinically apparent acute liver injury.